NEWS DETAIL

  • Source : Press Release
  • Date : 2021-01-15
  • Event type : Marketed
  • Companies : Catalent, Inc.

Catalent Entered Into a Long-term Supply Agreement with Acorda for INBRIJA

"Catalent has also entered into a long-term supply agreement with Acorda Therapeutics to continue commercial manufacture of INBRIJA® (levodopa inhalation powder) from the Chelsea facility. INBRIJA is a prescription medicine from Acorda Therapeutics indicated for use when needed with hypomobility or OFF episodes in adults with Parkinson's disease treated with regular carbidopa/levodopa medicine."



Sourced from the news: https://www.pharmacircle.com/one_news.php?id=560234